Emerging Opportunities for the Combination of Molecularly Targeted Drugs with Radiotherapy

Clinical Oncology

Volumn 26, Issue 5, 2014, Pages 266-276

  Searle, E J ^a,b   Illidge, T M ^b   Stratford, I J ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Molecularly targeted drugs; Radiation; Radiosensitisers; Radiotherapy

Indexed keywords

CELECOXIB; EPIDERMAL GROWTH FACTOR RECEPTOR; VASCULOTROPIN; ANTINEOPLASTIC AGENT; CYCLOOXYGENASE 2 INHIBITOR; PYRAZOLE DERIVATIVE; RADIOSENSITIZING AGENT; SULFONAMIDE; VASCULOTROPIN A;

ANGIOGENESIS; ARTICLE; BRAIN METASTASIS; CANCER CONTROL; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CANCER STEM CELL; CHEMORADIOTHERAPY; CLINICAL TRIAL (TOPIC); GLIOMA; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; LUNG NON SMALL CELL CANCER; MOLECULARLY TARGETED THERAPY; NASOPHARYNX CARCINOMA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; QUALITY OF LIFE; RADIOSENSITIVITY; TUMOR GROWTH; DRUG EFFECTS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PROCEDURES; RADIATION RESPONSE;

ANTINEOPLASTIC AGENTS; CHEMORADIOTHERAPY; CLINICAL TRIALS AS TOPIC; CYCLOOXYGENASE 2 INHIBITORS; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PYRAZOLES; RADIATION-SENSITIZING AGENTS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SULFONAMIDES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84898043674     PISSN: 09366555     EISSN: 14332981     Source Type: Journal    
DOI: 10.1016/j.clon.2014.02.006     Document Type: Article

References (87)

1. Department of Health. Radiotherapy Services in England 2012. Available at: [accessed 24.01.14]. https://www.gov.uk/government/publications/radiotherapy-services-in-england-2012.
2. Brown P.D., Krishnan S., Sarkaria J.N., et al. Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177. JClin Oncol 2008, 26:5603-5609.
3. Broniscer A., Baker S.J., Stewart C.F., et al. Phase I and pharmacokinetic studies of erlotinib administered concurrently with radiotherapy for children, adolescents, and young adults with high-grade glioma. Clin Cancer Res 2009, 15:701-707.
4. Prados M.D., Chang S.M., Butowski N., et al. Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. JClin Oncol 2009, 27:579-584.
5. Lind J.S.W., Lagerwaard F.J., Smit E.F., et al. Phase I study of concurrent whole brain radiotherapy and erlotinib for multiple brain metastases from non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2009, 74:1391-1396.
6. Peereboom D., Shepard D., Ahluwalia M., et al. Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme. JNeurooncol 2010, 98:93-99.
7. Herchenhorn D., Dias F.L., Viegas C.M.P., et al. Phase I/II study of erlotinib combined with cisplatin and radiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 2010, 78:696-702.
8. Hainsworth J.D., Spigel D.R., Greco F.A., et al. Combined modality treatment with chemotherapy, radiation therapy, bevacizumab, and erlotinib in patients with locally advanced squamous carcinoma of the head and neck: a phase II trial of the Sarah Cannon Oncology Research Consortium. Cancer J 2011, 17:267-272. 10.1097/PPO.0b013e3182329791.
9. Robertson J.M., Margolis J., Jury R.P., et al. Phase I study of conformal radiotherapy and concurrent full-dose gemcitabine with erlotinib for unresected pancreatic cancer. Int J Radiat Oncol Biol Phys 2012, 82:e187-e192.
10. Gilbert J., Rudek M.A., Higgins M.J., et al. A phase I trial of erlotinib and concurrent chemoradiotherapy for stage III and IV (M0) squamous cell carcinoma of the head and neck. Clin Cancer Res 2012, 18:1735-1742.
11. Martins R.G., Parvathaneni U., Bauman J.E., et al. Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: a randomized phase II trial. JClin Oncol 2013, 31:1415-1421.
12. Rao K., Kalapurakal S., Chalasani P., et al. Aphase II study of intra-arterial cisplatin with concurrent radiation and erlotinib for locally advanced head and neck cancer. Cancer Chemother Pharmacol 2013, 72:545-552.
13. Heath C.H., Deep N.L., Nabell L., et al. Phase 1 study of erlotinib plus radiation therapy in patients with advanced cutaneous squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2013, 85:1275-1281.
14. Sperduto P.W., Wang M., Robins H.I., et al. Aphase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: Radiation Therapy Oncology Group 0320. Int J Radiat Oncol Biol Phys 2013, 85:1312-1318.
15. Welsh J.W., Komaki R., Amini A., et al. Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer. JClin Oncol 2013, 31:895-902.
16. Iyer R., Chhatrala R., Shefter T., et al. Erlotinib and radiation therapy for elderly patients with esophageal cancer - clinical and correlative results from a prospective multicenter phase 2 trial. Oncology 2013, 85:53-58.
17. Raftery L., Tepper J.E., Goldberg R.M., et al. A two-cohort phase I study of weekly oxaliplatin and gemcitabine, then oxaliplatin, gemcitabine, and erlotinib during radiotherapy for unresectable pancreatic carcinoma. Am J Clin Oncol 2013, 36.
18. Sharp H., Morris J.C., Van Waes C., et al. High incidence of oral dysesthesias on a trial of gefitinib, paclitaxel, and concurrent external beam radiation for locally advanced head and neck cancers. Am J Clin Oncol 2008, 31(6):557-560.
19. Valentini V., De Paoli A., Gambacorta M.A., et al. Infusional 5-fluorouracil and ZD1839 (Gefitinib-Iressa) in combination with preoperative radiotherapy in patients with locally advanced rectal cancer: a phase I and II trial (1839IL/0092). Int J Radiat Oncol Biol Phys 2008, 72:644-649.
20. Ma S., Xu Y., Deng Q., et al. Treatment of brain metastasis from non-small cell lung cancer with whole brain radiotherapy andgefitinib in a Chinese population. Lung Cancer 2009, 65:198-203.
21. Olsen C.C., Schefter T.E., Chen H., et al. Results of a phase I trial of 12 patients with locally advanced pancreatic carcinoma combining gefitinib, paclitaxel, and 3-dimensional conformal radiation: report of toxicity and evaluation of circulating K-ras as a potential biomarker of response to therapy. Am J Clin Oncol 2009, 32:115-121.
22. Geyer J.R., Stewart C.F., Kocak M., et al. Aphase I and biology study of gefitinib and radiation in children with newly diagnosed brain stem gliomas or supratentorial malignant gliomas. Eur J Cancer 2010, 46:3287-3293.
23. Van Waes C., Allen C.T., Citrin D., et al. Molecular and clinical responses in a pilot study of gefitinib with paclitaxel and radiation in locally advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 2010, 77:447-454.
24. Center B., Petty W.J., Ayala D., et al. A phase I study of gefitinib with concurrent dose-escalated weekly docetaxel and conformal three-dimensional thoracic radiation followed by consolidative docetaxel and maintenance gefitinib for patients with stage III non-small cell lung cancer. J Thorac Oncol 2010, 5:69-74. http://dx.doi.org/10.1097/JTO.0b013e3181c59a0e.
25. Rodriguez C.P., Adelstein D.J., Rice T.W., et al. Aphase II study of perioperative concurrent chemotherapy, gefitinib, and hyperfractionated radiation followed by maintenance gefitinib in locoregionally advanced esophagus and gastroesophageal junction cancer. JThorac Oncol 2010, 5:229-235. 10.1097/JTO.0b013e3181c5e334.
26. Cohen E.E.W., Haraf D.J., Kunnavakkam R., et al. Epidermal growth factor receptor inhibitor gefitinib added to chemoradiotherapy in locally advanced head and neck cancer. JClin Oncol 2010, 28:3336-3343.
27. Joensuu G., Joensuu T., Nokisalmi P., et al. Aphase I/II trial of gefitinib given concurrently with radiotherapy in patients with nonmetastatic prostate cancer. Int J Radiat Oncol Biol Phys 2010, 78:42-49.
28. Ready N., Jänne P.A., Bogart J., et al. Chemoradiotherapy and gefitinib in stage III non-small cell lung cancer with epidermal growth factor receptor and KRAS mutation analysis: Cancer and Leukemia Group B (CALEB) 30106, a CALGB-stratified phase II trial. JThorac Oncol 2010, 5(9):1382-1390.
29. Gregoire V., Hamoir M., Chen C., et al. Gefitinib plus cisplatin and radiotherapy in previously untreated head and neck squamous cell carcinoma: a phase II, randomized, double-blind, placebo-controlled study. Radiother Oncol 2011, 100:62-69.
30. Pesce G.A., Klingbiel D., Ribi K., et al. Outcome, quality of life and cognitive function of patients with brain metastases from non-small cell lung cancer treated with whole brain radiotherapy combined with gefitinib or temozolomide. A randomised phase II trial of the Swiss Group for Clinical Cancer Research (SAKK 70/03). Eur J Cancer 2012, 48:377-384.
31. Chakravarti A., Wang M., Robins H.I., et al. RTOG 0211: a phase 1/2 study of radiation therapy with concurrent gefitinib for newly diagnosed glioblastoma patients. Int J Radiat Oncol Biol Phys 2013, 85:1206-1211.
32. Kimple R.J., Horton J.K., Livasy C.A., et al. Phase I study and biomarker analysis of lapatinib and concurrent radiation for locally advanced breast cancer. Oncologist 2012, 17:1496-1503.
33. Baumann M., Krause M., Dikomey E., et al. EGFR-targeted anti-cancer drugs in radiotherapy: preclinical evaluation of mechanisms. Radiother Oncol 2007, 83:238-248.
34. Ciardiello F., Tortora G. EGFR antagonists in cancer treatment. New Engl J Med 2008, 358:1160-1174.
35. Kelly K., Chansky K., Gaspar L.E., et al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. JClin Oncol 2008, 26:2450-2456.
36. Yoshida T., Yamada K., Azuma K., et al. Comparison of adverse events and efficacy between gefitinib and erlotinib in patients with non-small-cell lung cancer: a retrospective analysis. Med Oncol 2013, 30:1-7.
37. Rapisarda A., Melillo G. Role of the VEGF/VEGFR axis in cancer biology and therapy. Adv Cancer Res 2012, 114:237-267.
38. Kleibeuker E.A., Griffioen A.W., Verheul H.M., et al. Combining angiogenesis inhibition and radiotherapy: a double-edged sword. Drug Resist Updat 2012, 15:173-182.
39. Butowski N., Chang S.M., Lamborn K.R., et al. Enzastaurin plus temozolomide with radiation therapy in glioblastoma multiforme: a phase I study. Neuro-Oncology 2010, 12:608-613.
40. Butowski N., Chang S.M., Lamborn K.R., et al. Phase II and pharmacogenomics study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcoma. Neuro-Oncology 2011, 13:1331-1338.
41. Grønberg B.H., Ciuleanu T., Fløtten Ø., et al. Aplacebo-controlled, randomized phase II study of maintenance enzastaurin following whole brain radiation therapy in the treatment of brain metastases from lung cancer. Lung Cancer 2012, 78:63-69.
42. Wick W., Steinbach J.P., Platten M., et al. Enzastaurin before and concomitant with radiation therapy, followed by enzastaurin maintenance therapy, in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation. Neuro-Oncology 2013, 15:1405-1412.
43. Sarkaria J.N., Galanis E., Wu W., et al. North Central Cancer Treatment Group phase I trial N057K of everolimus (RAD001) and temozolomide in combination with radiation therapy in patients with newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys 2011, 81:468-475.
44. Hainsworth J.D., Shih K.C., Shepard G.C., et al. Phase II study of concurrent radiation therapy, temozolomide, and bevacizumab followed by bevacizumab/everolimus as first-line treatment for patients with glioblastoma. Clin Adv Hematol Oncol 2012, 10:240-246.
45. Chinnaiyan P., Won M., Wen P.Y., et al. RTOG 0913: a phase 1 study of daily everolimus (RAD001) in combination with radiation therapy and temozolomide in patients with newly diagnosed glioblastoma. Int J Radiat Oncol Biol Phys 2013, 86:880-884.
46. Hainsworth J.D., Ervin T., Friedman E., et al. Concurrent radiotherapy and temozolomide followed by temozolomide and sorafenib in the first-line treatment of patients with glioblastoma multiforme. Cancer 2010, 116:3663-3669.
47. Den R.B., Kamrava M., Sheng Z., et al. Aphase I study of the combination of sorafenib with temozolomide and radiation therapy for the treatment of primary and recurrent high-grade gliomas. Int J Radiat Oncol Biol Phys 2013, 85:321-328.
48. Meyer J.M., Perlewitz K.S., Hayden J.B., et al. Phase I trial of preoperative chemoradiation plus sorafenib for high risk extremity soft tissue sarcomas with dynamic contrast-enhanced MRI correlates. Clin Cancer Res 2013, 19(24):6902-6911.
49. Kao J., Packer S., Vu H.L., et al. Phase 1 study of concurrent sunitinib and image-guided radiotherapy followed by maintenance sunitinib for patients with oligometastases. Cancer 2009, 115:3571-3580.
50. Hui E.P., Ma B.B.Y., King A.D., et al. Hemorrhagic complications in a phase II study of sunitinib in patients of nasopharyngeal carcinoma who has previously received high-dose radiation. Ann Oncol 2011, 22:1280-1287.
51. Wuthrick E.J., Kamrava M., Curran W.J., et al. Aphase 1b trial of the combination of the antiangiogenic agent sunitinib and radiation therapy for patients with primary and metastatic central nervous system malignancies. Cancer 2011, 117:5548-5559.
52. Tong C.C.L., Ko E.C., Sung M.W., et al. Phase II trial of concurrent sunitinib and image-guided radiotherapy for oligometastases. PLoS ONE 2012, 7:e36979.
53. Corn P.G., Song D.Y., Heath E., et al. Sunitinib plus androgen deprivation and radiation therapy for patients with localized high-risk prostate cancer: results from a multi-institutional phase 1 study. Int J Radiat Oncol Biol Phys 2013, 86:540-545.
54. Broniscer A., Baker J.N., Tagen M., et al. Phase I study of vandetanib during and after radiotherapy in children with diffuse intrinsic pontine glioma. JClin Oncol 2010, 28:4762-4768.
55. Drappatz J., Norden A.D., Wong E.T., et al. Phase I study of vandetanib with radiotherapy and temozolomide for newly diagnosed glioblastoma. Int J Radiat Oncol Biol Phys 2010, 78:85-90.
56. Brandes A.A., Stupp R., Hau P., et al. EORTC study 26041-22041: phase I/II study on concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) with PTK787/ZK222584 (PTK/ZK) in newly diagnosed glioblastoma. Eur J Cancer 2010, 46:348-354.
57. Gerstner E., Eichler A., Plotkin S., et al. Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide. JNeurooncol 2011, 103:325-332.
58. Radiation Therapy Oncology Group. Sorafenib tosylate with or without stereotactic body radiation therapy in treating patients with liver cancer. Available at: [accessed 24.01.14]. http://clinicaltrials.gov/show/NCT01730937.
59. Choy H., Milas L. Enhancing radiotherapy with cyclooxygenase-2 enzyme inhibitors: a rational advance?. JNatl Cancer Inst 2003, 95:1440-1452.
60. Davis T.W., O'Neal J.M., Pagel M.D., et al. Synergy between celecoxib and radiotherapy results from inhibition of cyclooxygenase-2-derived prostaglandin E2, a survival factor for tumor and associated vasculature. Cancer Res 2004, 64:279-285.
61. Halamka M., Cvek J., Kubes J., et al. Plasma levels of vascular endothelial growth factor during and after radiotherapy in combination with celecoxib in patients with advanced head and neck cancer. Oral Oncol 2011, 47:763-767.
62. Debucquoy A., Roels S., Goethals L., et al. Double blind randomized phase II study with radiation+5-fluorouracil+/-celecoxib for resectable rectal cancer. Radiother Oncol 2009, 93:273-278.
63. Mutter R., Lu B., Carbone D.P., et al. Aphase II study of celecoxib in combination with paclitaxel, carboplatin, and radiotherapy for patients with inoperable stage IIIA/B non-small cell lung cancer. Clin Cancer Res 2009, 15:2158-2165.
64. Mohammadianpanah M., Razmjou-Ghalaei S., Mosalaei A., et al. Efficacy and safety of concurrent chemoradiation with weekly cisplatin ± low-dose celecoxib in locally advanced undifferentiated nasopharyngeal carcinoma: a phase II-III clinical trial. JCancer Res Therapeut 2011, 7:442-447.
65. Xue W.-P., Bai S.-M., Luo M., et al. Phase I clinical trial of nasopharyngeal radiotherapy and concurrent celecoxib for patients with locoregionally advanced nasopharyngeal carcinoma. Oral Oncol 2011, 47:753-757.
66. Gore E., Bae K., Langer C., et al. Phase I/II trial of a COX-2 inhibitor with limited field radiation for intermediate prognosis patients who have locally advanced non-small-cell lung cancer: Radiation Therapy Oncology Group 0213. Clin Lung Cancer 2011, 12:125-130.
67. Morak M.J.M., Richel D.J., van Eijck C.H.J., et al. Phase II trial of Uracil/Tegafur plus leucovorin and celecoxib combined with radiotherapy in locally advanced pancreatic cancer. Radiother Oncol 2011, 98:261-264.
68. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet 2013, 382:769-779. Collaboration CatNTC.
69. Rastogi M., Gupta M., Seam R., Revannasiddaiah S. Three concerns with regards to the utilization of COX-2 inhibitor (celecoxib) in combination with standard chemoradiotherapy for nasopharyngeal carcinoma. JCancer Res Therapeut 2012, 8:464.
70. Lenz H.-J. Clinical update: proteasome inhibitors in solid tumors. Cancer Treat Rev 2003, 29(Suppl. 1):41-48.
71. Davies A.M., Lara P.N., Mack P.C., Gandara D.R. Incorporating bortezomib into the treatment of lung cancer. Clin Cancer Res 2007, 13:4647s-4651s.
72. Grossman S.A., Ye X., Chamberlain M., et al. Talampanel with standard radiation and temozolomide in patients with newly diagnosed glioblastoma: a multicenter phase II trial. J Clin Oncol 2009, 27:4155-4161.
73. Haas-Kogan D.A., Banerjee A., Poussaint T.Y., et al. Phase II trial of tipifarnib and radiation in children with newly diagnosed diffuse intrinsic pontine gliomas. Neuro-Oncology 2011, 13:298-306.
74. Nghiemphu P.L., Wen P.Y., Lamborn K.R., et al. A phase I trial of tipifarnib with radiation therapy, with and without temozolomide, for patients with newly diagnosed glioblastoma. Int J Radiat Oncol Biol Phys 2011, 81:1422-1427.
75. Ree A.H., Dueland S., Folkvord S., et al. Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: the Pelvic Radiation and Vorinostat (PRAVO) phase 1 study. Lancet Oncol 2010, 11:459-464.
76. Kubicek G.J., Werner-Wasik M., Machtay M., et al. Phase I trial using proteasome inhibitor bortezomib and concurrent temozolomide and radiotherapy for central nervous system malignancies. Int J Radiat Oncol Biol Phys 2009, 74:433-439.
77. Edelman M.J., Burrows W., Krasna M.J., et al. Phase I trial of carboplatin/paclitaxel/bortezomib and concurrent radiotherapy followed by surgical resection in stage III non-small cell lung cancer. Lung Cancer 2010, 68:84-88.
78. Pugh T.J., Chen C., Rabinovitch R., et al. Phase I trial of bortezomib and concurrent external beam radiation in patients with advanced solid malignancies. Int J Radiat Oncol Biol Phys 2010, 78:521-526.
79. O'Neil B.H., Raftery L., Calvo B.F., et al. Aphase I study of bortezomib in combination with standard 5-fluorouracil and external-beam radiation therapy for the treatment of locally advanced or metastatic rectal cancer. Clin Colorectal Cancer 2010, 9:119-125.
80. Argiris A., Duffy A.G., Kummar S., et al. Early tumor progression associated with enhanced EGFR signaling with bortezomib, cetuximab, and radiotherapy for head and neck cancer. Clin Cancer Res 2011, 17:5755-5764.
81. Kubicek G.J., Axelrod R.S., Machtay M., et al. Phase I trial using the proteasome inhibitor bortezomib and concurrent chemoradiotherapy for head-and-neck malignancies. Int J Radiat Oncol Biol Phys 2012, 83:1192-1197.
82. Lao C., Friedman J., Tsien C., et al. Concurrent whole brain radiotherapy and bortezomib for brain metastasis. Radiat Oncol 2013, 8:204.
83. Jonsson Comprehensive Cancer Center. Bortezomib, temozolomide, and regional radiation therapy in treating patients with newly diagnosed glioblastoma multiforme or gliosarcoma. Available at: [accessed 24.01.14]. http://clinicaltrials.gov/show/NCT00998010.
84. ® (Bortezomib) in combination with Temozolomide and regional radiation therapy for upfront treatment of patients with newly-diagnosed glioblastoma multiforme. Neuro-Oncology 2013, 15:iii75-iii84.
85. National Institute for Health and Care Excellence. Cetuximab for the treatment of locally advanced squamous cell cancer of the head and neck TA145. Available at: [accessed 24.01.14]. http://publications.nice.org.uk/cetuximab-for-the-treatment-of-locally-advanced-squamous-cell-cancer-of-the-head-and-neck-ta145.
86. Lin S.H., George T.J., Ben-Josef E., et al. Opportunities and challenges in the era of molecularly targeted agents and radiation therapy. J Nat Cancer Inst 2013, 105(10):686-693.
87. Bendszus M., Debus J., Wick W., et al. APG101_CD_002: a phase II, randomized, open-label, multicenter study of weekly APG101 plus reirradiation versus reirradiation in the treatment of patients with recurrent glioblastoma. J Clin Oncol 2012, 30(Suppl. 15). Abstract 2034.